Lung Cancer Drug Resistance: Causes & Treatment Strategies
Summary of Lung Cancer Resistance Mechanisms & Treatment Strategies (ESMO 2025)
This article, presented at the European Society for Medical Oncology 2025 congress, details the complexities of resistance in lung cancer and potential strategies to overcome it, as discussed by Pasi A. Jänne, MD. Here’s a breakdown of the key takeaways:
1. Origins of Resistance:
* Pre-existing Resistant Clones: Subpopulations of tumor cells already possess resistance mechanisms before treatment.
* Drug Tolerance State: Tumor cells survive initial therapy, entering a reversible state where they maintain some sensitivity but can acquire resistance over time.
* Heterogeneity: Resistance is complex and often involves multiple pathways developing together (secondary mutations, bypass signaling, histologic change).
2.Preventing Resistance:
* Potent Inhibitors: Developing drugs that overcome resistance to older generations (e.g., osimertinib for EGFR T790M, lorlatinib for ALK mutations).
* Combination Therapies: Pairing targeted inhibitors with othre agents to improve response rates and delay resistance. Examples include:
* Osimertinib + MET inhibitors (capmatinib, savolitinib) for patients with MET amplification/expression.
* Biomarker-driven approaches are crucial for selecting effective combinations.
3. Targeting Drug-Tolerant, Persistent Cancer:
* Characteristics: These cells survive initial therapy and exhibit stem cell-like properties, slow cycling, EMT characteristics, and epigenetic modulation.
* Potential Strategies:
* Local Therapies: Consolidated radiation to residual lesions shows promise.
* novel Systemic therapies: Preclinical models suggest potential for:
* CAR T-cell therapy: Showed durable cures in a mouse model where osimertinib and ADCs failed.
* Eliminating the “intermediate population” (cells surviving therapy but not fully resistant) could extend the benefit of first-line therapy.
4. Addressing Acquired Resistance:
* Occurs when tumors initially respond but later progress.
* The pattern of progression (systemic vs. focal) guides subsequent treatment decisions (details not fully elaborated in this excerpt).
overall Message: Lung cancer resistance is a multifaceted problem requiring a nuanced approach. Strategies focusing on preventing resistance through potent inhibitors and combinations, targeting drug-tolerant cells, and understanding the patterns of acquired resistance are crucial for improving patient outcomes. Biomarker-driven approaches are key to tailoring treatment effectively.